Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “High-risk Plasma Cell Neoplasms”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07410494
What this trial is testing

Biomarker-Guided Allogeneic Single-Target or Dual-Target CAR-NK Cell Therapy for Advanced Solid Tumors

Who this might be right for
CancerBreast CancerNon-Small Cell Lung Cancer (NSCLC)+10 more
Essen Biotech 85
Early research (Phase 1)UnknownNCT01619761
What this trial is testing

NK Cells in Cord Blood Transplantation

Who this might be right for
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 PositiveAcute Biphenotypic LeukemiaAcute Lymphoblastic Leukemia in Remission+22 more
M.D. Anderson Cancer Center 13
Testing effectiveness (Phase 2)Ended earlyNCT01453088
What this trial is testing

Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

Who this might be right for
Multiple Myeloma
Hackensack Meridian Health 63
Testing effectiveness (Phase 2)UnknownNCT03570983
What this trial is testing

A Trial Comparing Single Agent Melphalan to Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) as a Preparative Regimen for Patients With Multiple Myeloma Undergoing High Dose Therapy Followed by Autologous Stem Cell Reinfusion

Who this might be right for
Multiple Myeloma
Swedish Medical Center 100
Testing effectiveness (Phase 2)Study completedNCT00046852
What this trial is testing

Chemotherapy and Peripheral Stem Cell Transplantation Followed By Immunotherapy in Treating Patients With Multiple Myeloma

Who this might be right for
InfectionMultiple Myeloma and Plasma Cell Neoplasm
University of Maryland, Baltimore
Early research (Phase 1)Ended earlyNCT00963495
What this trial is testing

Study Evaluating the Tolerance and Biological Activity of Oral Clioquinol in Patients With Relapsed or Refractory Hematological Malignancy

Who this might be right for
Acute Myeloid LeukemiaAcute Lymphocytic LeukemiaChronic Lymphocytic Leukemia+4 more
University Health Network, Toronto 11
Testing effectiveness (Phase 2)Study completedNCT00847639
What this trial is testing

Safety Study of Lenalidomide Maintenance Therapy Post Allogeneic HCT for High-risk Multiple Myeloma

Who this might be right for
Multiple Myeloma
Center for International Blood and Marrow Transplant Research 30
Large-scale testing (Phase 3)Study completedNCT02180867
What this trial is testing

Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery

Who this might be right for
Alveolar Soft Part SarcomaAngiomatoid Fibrous HistiocytomaAtypical Fibroxanthoma+33 more
National Cancer Institute (NCI) 140
Testing effectiveness (Phase 2)Active Not RecruitingNCT05849610
What this trial is testing

Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

Who this might be right for
High-Risk de Novo Multiple Myeloma
PETHEMA Foundation 30
Testing effectiveness (Phase 2)Looking for participantsNCT06140524
What this trial is testing

A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma

Who this might be right for
Monoclonal Gammopathy of Undetermined Significance (MGUS)Smoldering Multiple Myeloma (SMM)
Regeneron Pharmaceuticals 116
Early research (Phase 1)Study completedNCT00477815
What this trial is testing

Rituximab, Yttrium Y 90 Ibritumomab Tiuxetan, Melphalan, and Autologous Peripheral Stem Cell Transplant in Treating Patients With Previously Treated Multiple Myeloma

Who this might be right for
Multiple Myeloma and Plasma Cell Neoplasm
Mayo Clinic 30
Testing effectiveness (Phase 2)Looking for participantsNCT07523555
What this trial is testing

Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies

Who this might be right for
Relapsed/Refractory B-cell Acute Lymphoblastic LeukemiaRelapsed/Refractory B-cell Non-Hodgkin Lymphoma or CLL/SLLRelapsed/Refractory Multiple Myeloma or Plasma Cell Leukemia+4 more
Beijing Biotech 96
Testing effectiveness (Phase 2)Study completedNCT01690143
What this trial is testing

Carfilzomib + High Dose Melphalan as Preparative Regimen for Autologous Hematopoietic Stem Cell Transplantation

Who this might be right for
Multiple Myeloma
University of Alabama at Birmingham 45
Not applicableLooking for participantsNCT06245629
What this trial is testing

Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

Who this might be right for
Myeloma Multiple
Uppsala University 100
Testing effectiveness (Phase 2)Ended earlyNCT01239368
What this trial is testing

Th1/Tc1 Immunotherapy Following Stem Cell Transplantation in Multiple Myeloma

Who this might be right for
Myeloma, Plasma-CellMyeloma-MultipleMyelomatosis
National Cancer Institute (NCI) 34
Testing effectiveness (Phase 2)Looking for participantsNCT04025450
What this trial is testing

Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

Who this might be right for
Multiple Myeloma
The First Affiliated Hospital of Soochow University 50
Testing effectiveness (Phase 2)Study completedNCT00586014
What this trial is testing

High Dose Sequential Therapy and Autologous Stem Cell Rescue for Multiple Myeloma

Who this might be right for
Multiple Myeloma
Duke University 91
Testing effectiveness (Phase 2)Looking for participantsNCT05632380
What this trial is testing

ASCT in Combination With C-CAR088 for Treating Patients With Ultra High-risk Multiple Myeloma (MM)

Who this might be right for
Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China 20
Large-scale testing (Phase 3)Active Not RecruitingNCT03710603
What this trial is testing

Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

Who this might be right for
Multiple Myeloma
Stichting European Myeloma Network 709
Testing effectiveness (Phase 2)Study completedNCT01352286
What this trial is testing

Redirected Auto T Cells for Advanced Myeloma

Who this might be right for
Multiple Myeloma
GlaxoSmithKline 25
Next Page